Peripheral Arteriopathy Rate In Stroke - Full Text View

Sponsor:	University of Erlangen-Nürnberg
Information provided by:	University of Erlangen-Nürnberg
ClinicalTrials.gov Identifier:	NCT00794066

Purpose

Purpose:

To assess the prevalence of peripheral arterial disease (PAD) in acute stroke patients.

Interventions:

Assessment of the ankle brachial index using the "boso-ABI-system 100" (www.boso.de).

Design:

Prospective, controlled, open, cohort study.

Study size planned:

1000.

Follow-up duration:

6 months.

Condition	Intervention
Peripheral Artery Disease	Procedure: measuring the ankle brachial index

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Prevalence of Peripheral Arterial Disease in Acute Ischemic and Hemorrhagic Stroke Patients

Further study details as provided by University of Erlangen-Nürnberg:

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	1000
Study Start Date:	August 2008
Estimated Study Completion Date:	December 2010
Estimated Primary Completion Date:	June 2010 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
1 Control	Procedure: measuring the ankle brachial index Assessment of the ankle brachial index using the "boso-ABI-system 100" (www.boso.de).
2 TIA	Procedure: measuring the ankle brachial index Assessment of the ankle brachial index using the "boso-ABI-system 100" (www.boso.de).
3 Ischemic stroke	Procedure: measuring the ankle brachial index Assessment of the ankle brachial index using the "boso-ABI-system 100" (www.boso.de).
4 Hemorrhagic stroke	Procedure: measuring the ankle brachial index Assessment of the ankle brachial index using the "boso-ABI-system 100" (www.boso.de).

Eligibility

Study Population

consecutive patients with acute ischemic or hemorhagic stroke.

Criteria

Inclusion Criteria:

All consecutive adult patients with acute ischemic or hemorrhagic stroke. Matched concurrent non-stroke and non-TIA patients.

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00794066

Contacts

Contact: Hagen B. Huttner, MD	+4991318544523	hagen.huttner@uk-erlangen.de
Contact: Martin Köhrmann, MD	+4991318544544	martin.koehrmann@uk-erlangen.de

Locations

Germany
Department of Neurology, University of Erlangen, Germany	Recruiting
Erlangen, Germany, 91054
Contact: Hagen B. Huttner, MD +4991318544523 hagen.huttner@uk-erlangen.de
Contact: Martin Köhrmann, MD +4991318544544 martin.koehrmann@uk-erlangen.de
Principal Investigator: Hagen B. Huttner, MD
Principal Investigator: Martin Köhrmann, MD
Principal Investigator: Peter D. Schellinger, MD

Sponsors and Collaborators

University of Erlangen-Nürnberg

Investigators

Study Director:

Stefan Schwab, MD

Head of the Department of Neurology, University of Erlangen, Germany

More Information

No publications provided

Responsible Party:	Department of Neurology, University of Erlangen, Germany ( Department of Neurology, University of Erlangen, Germany )
Study ID Numbers:	DE-ER-2008-PARIS
Study First Received:	November 18, 2008
Last Updated:	November 18, 2008
ClinicalTrials.gov Identifier:	NCT00794066 History of Changes
Health Authority:	Germany: Ethics Commission

Keywords provided by University of Erlangen-Nürnberg:

PAD
Stroke
ICH
prevalence

Additional relevant MeSH terms:

Peripheral Vascular Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on November 20, 2009